The historical rank and industry rank for Modus Therapeutics Holding AB's EV-to-FCF or its related term are showing as below:
FRA:99Z'
s EV-to-FCF Range Over the Past 10 Years
Min: -2.63 Med: 0 Max: 0
Current: -2.63
FRA:99Z's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs FRA:99Z: -2.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Modus Therapeutics Holding AB (FRA:99Z) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Modus Therapeutics Holding AB's PE Ratio (TTM) for today is calculated as:
Modus Therapeutics Holding AB's share price for today is €0.021.
Modus Therapeutics Holding AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Modus Therapeutics Holding AB EV-to-FCF Related Terms
Modus Therapeutics Holding AB EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Modus Therapeutics Holding AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Modus Therapeutics Holding AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Modus Therapeutics Holding AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Modus Therapeutics Holding AB's EV-to-FCF falls into.
Modus Therapeutics Holding AB's current Enterprise Value is €4.38 Mil.
Modus Therapeutics Holding AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modus Therapeutics Holding AB (FRA:99Z) has a EV-to-FCF of -2.59 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Modus Therapeutics Holding AB and its competitors. According to the industry distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 336 companies in the Biotechnology industry.
Is Modus Therapeutics Holding AB's EV-to-FCF too high?
Modus Therapeutics Holding AB's current EV-to-FCF is -2.59. Based on the distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Modus Therapeutics Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Modus Therapeutics Holding AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Modus Therapeutics Holding AB ranks #999999 out of 336 companies for EV-to-FCF. This places Modus Therapeutics Holding AB in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Modus Therapeutics Holding AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modus Therapeutics Holding AB's current EV-to-FCF is -2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modus Therapeutics Holding AB stock overvalued right now?
Modus Therapeutics Holding AB (FRA:99Z) has a current EV-to-FCF of -2.59. The current EV-to-FCF is -2.59. Modus Therapeutics Holding AB's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Modus Therapeutics Holding AB (FRA:99Z), the current EV-to-FCF is -2.59 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modus Therapeutics Holding AB Business Description
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
30GF Score
Get the complete analysis for FRA:99Z
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:99Z has been successfully added to your 
